22 filings
8-K
GLTO
Galecto Inc
26 Mar 24
Other Events
4:00pm
8-K
GLTO
Galecto Inc
21 Dec 23
Other Events
4:30pm
8-K
GLTO
Galecto Inc
23 Oct 23
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
9:00am
8-K
GLTO
Galecto Inc
2 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:00pm
8-K
GLTO
Galecto Inc
26 Sep 23
Galecto Announces Plans to Explore Strategic Alternatives
4:05pm
8-K
9jo h5iyc
15 Aug 23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
8:00am
8-K
7mb8nm0vp 2tn74x
15 Jun 23
Submission of Matters to a Vote of Security Holders
4:00pm
8-K
3mi84w16pnv33j28
10 Mar 23
Regulation FD Disclosure
3:07pm
8-K
xbz24hf08a6n
6 Jan 23
Results of Operations and Financial Condition
7:01am
8-K
iikm17gew szu
31 Oct 22
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022
9:00am
8-K
5e1e9o kt
29 Sep 22
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
7:00am
8-K
xfm krrs9avswmrnqm
17 Jun 22
Submission of Matters to a Vote of Security Holders
7:00am
8-K
rauemjl2gb qtow7
9 Feb 22
Departure of Directors or Certain Officers
4:30pm
8-K
1dg4519n t59b
27 Jan 22
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
8:31am
8-K
x0a2lycc
5 Jan 22
Regulation FD Disclosure
4:02pm
8-K
owwcju6t s539li2
6 Jul 21
Departure of Directors or Certain Officers
9:00am
8-K
jjkko
28 May 21
Submission of Matters to a Vote of Security Holders
9:00am
8-K
y272mo69x7
15 Mar 21
Regulation FD Disclosure
7:52am
8-K
941av4adw4sao6jqx4
8 Jan 21
Galecto Appoints Anne Prener to its Board of Directors
8:15am
8-K
chknmamqz0n3 onvc
5 Jan 21
Results of Operations and Financial Condition
4:31pm